Several clinical trial evidences support this, for instance, Tang et al. reported the first-in-man CD33+ CAR-NK-92 cell clinical trial, testing safety in patients with AML experiencing relapsed and refractory conditions. This evidence concerns the gene CD33 and acute myeloid leukemia.